WHO ICTRP trial
Efficacy and safety of teniposide, cyclophosphamide and dexamethasone…
ChiCTR-OIC-15007636 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-OIC-15007636 |
|---|---|
| Public title | Efficacy and safety of teniposide, cyclophosphamide and dexamethasone combination in transplant-ineligible patients with relapsed/refractory multiple myeloma: a phase 2, single center, single arm study |
| Scientific title | Efficacy and safety of teniposide, cyclophosphamide and dexamethasone combination in transplant-ineligible patients with relapsed/refractory multiple myeloma: a phase 2, single center, single arm study |
| Primary sponsor | Sun Yat-sen University Cancer Center |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | II (Phase II study) |
| Countries | China |
| Conditions | Multiple Myeloma |
| Interventions | Treatment Group:VM26+CTX+DXM regimen |
| Registration date | Dec 17, 2015 |
| Target size | Treatment Group:40 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: